This study randomly assigned participants to receive daily, low-dose antibiotic prophylaxis (n=120) or methenamine hippurate (n=120) for 12 months. Treatment allocation was not masked, and crossover between arms was permitted. The primary clinical outcome measure was the incidence of symptomatic, antibiotic-treated UTI episodes reported by participants over the treatment period. The urinary antiseptic methenamine hippurate was found to be noninferior to prophylactic antibiotics in preventing urinary tract infections (UTIs) in women who had them repeatedly. Results were published March 9 by The British Medical Journal (BMJ).

A meta-analysis published in JAMA Internal Medicine has concluded that the link between statin-induced LDL lowering and reduction of CV outcomes may not be as robust as previously assumed. According to the researchers, the absolute risk reduction associated with statin use for all-cause mortality was 0.8% (95% CI, 0.4-1.2), whereas for MI it was 1.3% (95% CI, 0.9-1.7) and for stroke it was 0.4% (95% CI, 0.2-0.6). Absolute risk reduction figures were slightly higher for secondary prevention than for primary prevention.

A class action lawsuit against TeamHealth has concluded with a $15 million award settlement to be shared by some 3,000 emergency physicians in almost every US state. The doctors named in the court case alleged that TeamHealth, one of the nation’s largest medical staffing companies with 15,000 physicians, and its subsidiary Paragon Contracting Services, LLC, were in breach of their contracts and secretly cheated doctors out of a portion of the bonuses they were promised. The physicians claimed that their contracts required TeamHealth to pay them a bonus when they supervised care provided by a physician assistant, nurse practitioner, or other advanced practice provider (APP), but that did not happen.

The American Academy of Sleep Medicine (AASM) is taking issue with the US Senate’s recently passed legislation that will make daylight saving time (DST) permanent starting in 2023. AASM cautions that this permanent change would lead to health risks that include adverse cardiovascular events, mood disorders, and motor vehicle crashes. The group advocates for establishing permanent standard time instead.

Matthew Lunning, DO, Associate Vice Chair of Research at the University of Nebraska Medical Center, reviews treatment implications of emerging research in CAR T-cell therapy for a variety of lymphomas subtypes, and discusses newer study outcomes, limitations to current CAR-T cell products, the state of allogenic CAR-T cell therapy, and key elements to consider when selecting therapy for a given patient.

The authors analyzed a cohort of nearly 5,000 patients with AML for the prevalence and prognostic impact of IDH mutations and found distinct clinical and co-mutational features of the IDH1-R132C mutation. The study identified variable outcomes associated with distinct mutations of IDH and offers additional evidence in support of delineating the IDH2-R172K mutation as a distinct entity based on its co-mutational landscape and significant impact on outcome.